Barr Labs receives FDA nod for generic Yasmin
Barr Pharmaceuticals Inc. announced that its subsidiary, Barr Laboratories Inc., has received final approval from the FDA for its Abbreviated New Drug Application (ANDA) to manufacture and market a generic version of Yasmin (drospirenone and ethinyl estradiol). Yasmin is an oral contraceptive product manufactured and marketed by Bayer Schering Pharma AG.
- Barr Pharma receives FDA nod for generic Mirapex
- Ranbaxy receives provisional FDA nod for generic Nexium
- Mylan receives FDA nod for generic Plendil
- APP receives FDA nod for its two generics
